ReviewDigestive diseases and sciences2026
Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases-Current Clinical Approach.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Gut-Immune-Brain Axis in Aging: Integrating Immunosenescence, Inflammaging, and Neuroinflammation for Precision Medicine.Medical sciences (Basel, Switzerland) · 2026Review
- Buffer stabilized sodium butyrate enhances early growth and gut barrier function in broilers by modulating SCFA, antioxidant, and microbiota composition.BMC veterinary research · 2026Article
- Differential impact of sodium butyrate forms on intestinal morphology, gene expression, and growth performance in broiler chickens under cold stress at high altitude.Veterinary and animal science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, the importance of butyrate in prevention and health promotion in human health has been revealed and many publications have highlighted its role as a key component for intestinal functioning. Recent findings show that sodium butyrate has anti-inflammatory and immuno-modulatory activities in intestinal diseases and may be used in the therapy of intestinal diseases. Sodium butyrate mitigates mucosal inflammation and oxidative status, restores the damaged epithelial barrier, and modulates visceral sensitivity and intestinal motility. Novel forms of encapsulation are being developed to improve the effectiveness of sodium butyrate, as well as its palatability and patient's compliance
methodsWe conducted a comprehensive literature review. In this review, we discuss the utility, efficacy and safety of sodium butyrate preparations, including different microencapsulated forms in the management of main intestinal diseases, primarily inflammatory bowel diseases, irritable bowel syndrome and diverticular disease. . RESULTS AND
conclusionsAdvanced microencapsulated sodium butyrate preparations seem to be an promising form that could be used as add-on therapy for intestinal diseases. Due to butyrate's rapid epithelial absorption and local activity in the digestive tract, clinical outcomes may depend not only on the active ingredient but also on the delivery technology, release profile, and dosage. Therefore, we suggest that clinical results should be assessed in relation to specific preparations. Our summary confirms that specific microencapsulated versions, including those utilizing the MSB
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.